Repository logo
 
Publication

Nucleic acids delivery systems: a challenge for pharmaceutical technologists

2015Journal article Restricted access
Simple item page
dc.contributor.authorSilva, Ana Catarina
dc.contributor.authorLopes, Carla Martins
dc.contributor.authorLobo, José M. Sousa
dc.contributor.authorAmaral, M. Helena
dc.date.accessioned2020-10-02T08:18:34Z
dc.date.available2020-10-02T08:18:34Z
dc.date.issued2015
dc.date.updated2020-07-24T15:37:16Z
dc.description.abstractNucleic acids (NA) therapies, including therapy with genes, aptamers or antisense oligonucleotides, have been showing promising results, especially in the treatment of severe diseases (e.g. cancer and AIDS). Nevertheless, the full success of medical treatments requires efficient achievement of the therapeutic target and also the safety and effectiveness of the pharmaceutical system. NA are not very efficient when administered alone, which means that the use of appropriate methods for in vivo transfection of these molecules into targeted cells is fundamental. Examples of these techniques are the use of viral and non-viral vectors to transfer the NA to the cells nucleus. Despite viral vectors have been demonstrating superior effectiveness for NA transfer, some drawbacks have been pointed out, which focused the research in the non-viral vectors. However, the development of effective NA delivery systems remains a challenge for pharmaceutical technologists, mainly because of their in vivo failure, which hinders their clinical application. In this review article we address the characteristics of NA molecules and their respective limitations for formulation and administration. An update on the state of the art related to the latest and outstanding developments from the in vivo applications of NA viral and non-viral delivery systems is also presented. From this review, we can conclude that there is a lack of research regarding pre-clinical studies in specific animal models of disease, which is required for further human clinical trials and for their use in clinics.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.eid2-s2.0-84937131381
dc.identifier.issn1875-5453
dc.identifier.slugcv-prod-1252829
dc.identifier.urihttp://hdl.handle.net/10284/9015
dc.language.isoengpt_PT
dc.subjectDNApt_PT
dc.subjectLipoplexespt_PT
dc.subjectNon-viral delivery systemspt_PT
dc.subjectNucleic acidspt_PT
dc.subjectPolyplexespt_PT
dc.subjectRNApt_PT
dc.subjectViral delivery systemspt_PT
dc.titleNucleic acids delivery systems: a challenge for pharmaceutical technologistspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage16pt_PT
oaire.citation.issue1pt_PT
oaire.citation.startPage3pt_PT
oaire.citation.titleCurrent Drug Metabolismpt_PT
oaire.citation.volume16pt_PT
person.familyNameSilva
person.familyNameLopes
person.givenNameAna Catarina
person.givenNameCarla
person.identifier953153
person.identifier.ciencia-id5C1D-ED22-0D64
person.identifier.ciencia-id901D-160C-633E
person.identifier.orcid0000-0001-6923-0232
person.identifier.orcid0000-0001-5080-032X
person.identifier.ridF-1875-2017
person.identifier.ridM-4689-2016
person.identifier.scopus-author-id57028697500
person.identifier.scopus-author-id26649517700
rcaap.cv.cienciaid901D-160C-633E | Carla Martins Lopes
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication67e7f707-32ec-444a-a20d-a17f8e6e7c21
relation.isAuthorOfPublicationd2a48cfe-9258-4916-99be-bbcb710f6605
relation.isAuthorOfPublication.latestForDiscovery67e7f707-32ec-444a-a20d-a17f8e6e7c21

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Current_Drug_Metabolism,_2015,_16,_3-16.pdf
Size:
826.99 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.64 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

FCS (DCF) - Artigos em Revistas Científicas Internacionais com Arbitragem Científica